Navigation Links
Amylin Pharmaceuticals to Webcast Second Quarter Results
Date:7/14/2009

SAN DIEGO, July 14 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will webcast its Quarterly Update Conference Call for the second quarter of 2009 on Tuesday, July 21, 2009 at 5:00 p.m. ET/2:00 p.m. PT. Daniel M. Bradbury, Amylin's president and chief executive officer, will lead the call. On the same date post-market, Amylin will release financial results for the second quarter of 2009.

The call will be webcast live through Amylin's corporate Web site and a recording will be made available following the close of the call. To access the webcast, please log on to www.amylin.com approximately fifteen minutes prior to the call to register, download and install any necessary audio software. For those without access to the Internet, the live call may be accessed by phone by calling (866) 783-2141 (U.S./Canada) or (857) 350-1600 (international), Conference ID# 46259840. A replay of the call will also be available by phone beginning approximately two hours after the close of the call and can be accessed at (888) 286-8010 (U.S./Canada) or (617) 801-6888 (international), Conference ID# 67467542.

About Amylin

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California. Further information on Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Amylin Pharmaceuticals Announces Positive Results from Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment for Obesity
2. Amylin Pharmaceuticals to Present at Piper Jaffray Europe Conference
3. Amylin Pharmaceuticals to Present at Goldman Sachs Annual Global Health Care Conference
4. Amylin Announces Preliminary Tabulation of Annual Meeting Results
5. Amylin Responds to Eastbourne Letter
6. Amylin Comments on RiskMetrics Report
7. Amylin Pharmaceuticals to Present at Deutsche Bank Health Care Conference
8. Amylin Co-Founder Announces Plans to Vote for Eastbourne Slate
9. Amylin Pharmaceuticals Announces a New Sales Approach to Better Target the Diabetes Market
10. Amylin Issues Statement in Response to Carl Icahn
11. Icahn Asks Amylin to Allow Discussions With Eastbourne
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... May 25, 2016 , ... Biohaven Pharmaceutical Holding Company ... granted the company’s orphan drug designation request covering BHV-4157 for the treatment of ... the FDA. , Spinocerebellar ataxia is a rare, debilitating neurodegenerative disorder that ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... Last week, ... for corporate executives and entrepreneurs, held The Future of San Diego Life Science event ... San Diego life science community attended the event with speakers Dr. Rich Heyman, former ...
(Date:5/23/2016)... Ohio (PRWEB) , ... May 23, 2016 , ... ... Trends That Will Drive Precision Farming in 2017 and Beyond. The paper outlines ... practitioners in the precision ag industry. , “We’ve witnessed a lot of highs ...
(Date:5/23/2016)... LONDON , May 23, 2016 - ... by 40% - Frontage Implement a Single Platform to ... Compliance and Traceability Within the Bioanalytical lab Frontage Laboratories, ... the United States and China , ... its laboratory facilities. In addition to serving as the global electronic ...
Breaking Biology Technology:
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
(Date:4/28/2016)... First quarter 2016:   , ... the first quarter of 2015 The gross margin was ... 18.8) and the operating margin was 40% (-13) Earnings ... flow from operations was SEK 249.9 M (21.2) , ... SEK 7,000-8,500 M. The operating margin for 2016 is ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):